Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

If you are a Health Care Professional and interested in further details (including pathways being explored, mechanisms of action of investigational compounds, and an overall summary of investigational compounds organized by therapy area and disease state), please visit our in-depth Pfizer Immunology & Inflammation Research Pipeline site.

Inflammation Immunology Pipeline & Trials

Immunology Pipeline as of July 28, 2020

  • Discovery Projects
  • Phase 1
    3
  • Phase 2
    17
  • Phase 3
    3
  • Registration
    0
  • Total23
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK1 Inhibitor
Go to clinical trial
Atopic Dermatitis (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
ritlecitinib (PF-06651600)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ankylosing Spondylitis Phase 3 Product Enhancement Small Molecule
Eucrisa (crisaborole)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PDE4 Inhibitor
Stasis Dermatitis
Project advanced
Phase 2 Product Enhancement Small Molecule
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Ulcerative Colitis (Biologic) Phase 2 Product Enhancement Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
PF-06480605
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
TNFSF15 Blocker
Ulcerative Colitis (Biologic) Phase 2 New Molecular Entity Biologic
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
PF-06650833 / brepocitinib (PF-06700841) / PF-06826647
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4; TYK2/JAK1; TYK2 Inhibitor
Hidradenitis Suppurativa Phase 2 Product Enhancement Small Molecule
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Crohn's Disease Phase 2 Product Enhancement Small Molecule
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Vitiligo Phase 2 Product Enhancement Small Molecule
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Ulcerative Colitis Phase 2 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1
Alopecia Areata Phase 2 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1
Psoriatic Arthritis Phase 2 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1
Lupus Phase 2 Product Enhancement Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Psoriasis Phase 2 New Molecular Entity Small Molecule
PF-06823859
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
interferon, beta 1, fibroblast (IFNB1) Blocker
Inflammatory Disorders (Biologic) Phase 2 New Molecular Entity Biologic